Photo of G. Paolo Dotto,  MD, PhD

G. Paolo Dotto, MD, PhD

Massachusetts General Hospital

Massachusetts General Hospital
Phone: (617) 724-9538
Fax: (617) 726-4453


gdotto@partners.org

G. Paolo Dotto, MD, PhD

Massachusetts General Hospital

EDUCATIONAL TITLES

  • Biologist, Cutaneous Biology Research Center, Massachusetts General Hospital

DF/HCC PROGRAM AFFILIATION

Research Abstract

Dr. Dotto's main research interest has been control of epithelial tissue homeostasis and carcinogenesis, using skin as model system. His earlier work focused on the biochemical and cell-cell communication events underlying the onset of keratinocyte differentiation. His group was the first to implicate the cyclin/CDK inhibitor p21WAF1/Cip1 in control of keratinocyte differentiation and cancer formation, showing that this molecule can directly impact on gene transcription independently of the cell cycle. Notch activation in mammalian cells is commonly thought to enhance stem cell potential and promote tumorigenesis. Dr. Dotto showed instead that in keratinocytes Notch signaling is an important determinant of differentiation and tumor suppression, with p21 WAF1/Cip1 and p63 as critical targets. Little is known on control of Notch1 gene expression. His laboratory established this gene as a direct p53 target in antagonism to EGFR signaling, validating these findings for cancer development in the clinical setting. They also discovered a novel pro-differentiation and tumor suppressing function of calcineurin signaling in keratinocytes, with the ATF3 transcription factor as a critical target. This is of major clinical significance for the many patients under treatment with calcineurin inhibitors as immunosuppressants, who develop squamous cell carcinoma as a very frequent and often deadly complication. Epithelial-mesenchymal interactions play a key role in epithelial organ morphogenesis and homeostasis. In this context, the Dotto's group has pioneered research on an entirely novel and unexpected role of the Notch pathway in the mesenchymal compartment of the skin. His group showed that this pathway is critically required in dermal papilla cells for control and maintenance of the hair follicle cell fate. More recently, they showed that dermal fibroblast alterations can play a primary role in cutaneous field cancerization, with loss of Notch/CSL signaling and associated AP1 activation as underlying mechanisms.

Publications from Harvard Catalyst Profiles

Powered by Harvard Catalyst
  • Samarkina A, Youssef MK, Ostano P, Ghosh S, Ma M, Tassone B, Proust T, Chiorino G, Levesque MP, Goruppi S, Dotto GP. Androgen receptor is a determinant of melanoma targeted drug resistance. Nat Commun 2023; 14:6498. PubMed
  • Xu X, Tassone B, Ostano P, Katarkar A, Proust T, Joseph JM, Riganti C, Chiorino G, Kutalik Z, Lefort K, Dotto GP. HSD17B7 gene in self-renewal and oncogenicity of keratinocytes from Black versus White populations. EMBO Mol Med 2021; 13:e14133. PubMed
  • Özdemir BC, Dotto GP. Sex hormones and anticancer immunity. Clin Cancer Res 2019. PubMed
  • Özdemir BC, Csajka C, Dotto GP, Wagner AD. Sex Differences in Efficacy and Toxicity of Systemic Treatments: An Undervalued Issue in the Era of Precision Oncology. J Clin Oncol 2018; 36:2680-2683. PubMed
  • Özdemir BC, Dotto GP. Racial Differences in Cancer Susceptibility and Survival: More Than the Color of the Skin? Trends Cancer 2017; 3:181-197. PubMed
  • Dziunycz PJ, Neu J, Lefort K, Djerbi N, Freiberger SN, Iotzova-Weiss G, French LE, Dotto GP, Hofbauer GF. CYFIP1 is directly controlled by NOTCH1 and down-regulated in cutaneous squamous cell carcinoma. PLoS ONE 2017; 12:e0173000. PubMed
  • Ongusaha PP, Kim HG, Boswell SA, Ridley AJ, Der CJ, Dotto GP, Kim YB, Aaronson SA, Lee SW. RhoE Is a Pro-Survival p53 Target Gene that Inhibits ROCK I-Mediated Apoptosis in Response to Genotoxic Stress. Curr Biol 2016; 26:2221-2222. PubMed
  • Jo SH, Kim DE, Clocchiatti A, Dotto GP. PDCD4 is a CSL associated protein with a transcription repressive function in cancer associated fibroblast activation. 2016. PubMed
  • Menietti E, Xu X, Ostano P, Joseph JM, Lefort K, Dotto GP. Negative control of CSL gene transcription by stress/DNA damage response and p53. Cell Cycle 2016; 15:1767-78. PubMed
  • Lefort K, Ostano P, Mello-Grand M, Calpini V, Scatolini M, Farsetti A, Dotto GP, Chiorino G. Dual tumor suppressing and promoting function of Notch1 signaling in human prostate cancer. 2016. PubMed
  • Clocchiatti A, Cora E, Zhang Y, Dotto GP. Sexual dimorphism in cancer. Nat Rev Cancer 2016; 16:330-9. PubMed
  • Procopio MG, Laszlo C, Dotto GP. CSL-p53: From senescence to CAF activation. Cell Cycle 2016; 15:485-6. PubMed
  • Procopio MG, Laszlo C, Al Labban D, Kim DE, Bordignon P, Jo SH, Goruppi S, Menietti E, Ostano P, Ala U, Provero P, Hoetzenecker W, Neel V, Kilarski WW, Swartz MA, Brisken C, Lefort K, Dotto GP. Combined CSL and p53 downregulation promotes cancer-associated fibroblast activation. Nat Cell Biol 2015; 17:1193-204. PubMed
  • Dziunycz PJ, Lefort K, Wu X, Freiberger SN, Neu J, Djerbi N, Iotzowa-Weiss G, French LE, Dotto GP, Hofbauer GF. The oncogene ATF3 is potentiated by cyclosporine A and ultraviolet light A. J Invest Dermatol 2014. PubMed
  • Brooks YS, Ostano P, Jo SH, Dai J, Getsios S, Dziunycz P, Hofbauer GF, Cerveny K, Chiorino G, Lefort K, Dotto GP. Multifactorial ERβ and NOTCH1 control of squamous differentiation and cancer. J Clin Invest 2014; 124:2260-76. PubMed
  • Dotto GP. Multifocal epithelial tumors and field cancerization: stroma as a primary determinant. J Clin Invest 2014; 124:1446-53. PubMed
  • Dotto GP, Karine L. miR-34a/SIRT6 in squamous differentiation and cancer. Cell Cycle 2014; 13:1055-6. PubMed
  • Goruppi S, Dotto GP. Mesenchymal stroma: primary determinant and therapeutic target for epithelial cancer. Trends Cell Biol 2013; 23:593-602. PubMed
  • Lefort K, Brooks Y, Ostano P, Cario-André M, Calpini V, Guinea-Viniegra J, Albinger-Hegyi A, Hoetzenecker W, Kolfschoten I, Wagner EF, Werner S, Dotto GP. A miR-34a-SIRT6 axis in the squamous cell differentiation network. EMBO J 2013; 32:2248-63. PubMed
  • Kim JE, Won CH, Bak H, Kositratna G, Manstein D, Dotto GP, Chang SE. Gene profiling analysis of the early effects of ablative fractional carbon dioxide laser treatment on human skin. Dermatol Surg 2013. PubMed
  • Hu B, Castillo E, Harewood L, Ostano P, Reymond A, Dummer R, Raffoul W, Hoetzenecker W, Hofbauer GF, Dotto GP. Multifocal epithelial tumors and field cancerization from loss of mesenchymal CSL signaling. Cell 2012; 149:1207-20. PubMed
  • Dotto GP. p63 and FGFR: when development meets proliferation. EMBO Mol Med 2012; 4:165-7. PubMed
  • Ferrándiz N, Caraballo JM, García-Gutierrez L, Devgan V, Rodriguez-Paredes M, Lafita MC, Bretones G, Quintanilla A, Muñoz-Alonso MJ, Blanco R, Reyes JC, Agell N, Delgado MD, Dotto GP, León J. p21 as a transcriptional co-repressor of S-phase and mitotic control genes. PLoS ONE 2012; 7:e37759. PubMed
  • Restivo G, Nguyen BC, Dziunycz P, Ristorcelli E, Ryan RJ, Özuysal ÖY, Di Piazza M, Radtke F, Dixon MJ, Hofbauer GF, Lefort K, Dotto GP. IRF6 is a mediator of Notch pro-differentiation and tumour suppressive function in keratinocytes. EMBO J 2011. PubMed
  • Dotto GP. Calcineurin signaling as a negative determinant of keratinocyte cancer stem cell potential and carcinogenesis. Cancer Res 2011; 71:2029-33. PubMed
  • Hu B, Lefort K, Qiu W, Nguyen BC, Rajaram RD, Castillo E, He F, Chen Y, Angel P, Brisken C, Dotto GP. Control of hair follicle cell fate by underlying mesenchyme through a CSL-Wnt5a-FoxN1 regulatory axis. Genes Dev 2010; 24:1519-32. PubMed
  • Kang J, Yoo J, Lee S, Tang W, Aguilar B, Ramu S, Choi I, Otu HH, Shin JW, Dotto GP, Koh CJ, Detmar M, Hong YK. An exquisite cross-control mechanism among endothelial cell fate regulators directs the plasticity and heterogeneity of lymphatic endothelial cells. Blood 2010; 116:140-50. PubMed
  • Lyubimova A, Garber JJ, Upadhyay G, Sharov A, Anastasoaie F, Yajnik V, Cotsarelis G, Dotto GP, Botchkarev V, Snapper SB. Neural Wiskott-Aldrich syndrome protein modulates Wnt signaling and is required for hair follicle cycling in mice. J Clin Invest 2010; 120:446-56. PubMed
  • Wu, X. Nguyen, B. C. Dziunycz, P. Chang, S. Brooks, Y. Lefort, K. Hofbauer, G. F. Dotto, G. P.. Opposing roles for calcineurin and ATF3 in squamous skin cancer Nature 2010; 465:368-72.
  • Mandinova A, Kolev V, Neel V, Hu B, Stonely W, Lieb J, Wu X, Colli C, Han R, Pazin MJ, Pazin M, Ostano P, Dummer R, Brissette JL, Dotto GP. A positive FGFR3/FOXN1 feedback loop underlies benign skin keratosis versus squamous cell carcinoma formation in humans. J Clin Invest 2009; 119:3127-37. PubMed
  • Dotto GP. Notch tumor suppressor function. Oncogene 2008; 27:5115-23. PubMed
  • Kolev V, Mandinova A, Guinea-Viniegra J, Hu B, Lefort K, Lambertini C, Neel V, Dummer R, Wagner EF, Dotto GP. EGFR signalling as a negative regulator of Notch1 gene transcription and function in proliferating keratinocytes and cancer. Nat Cell Biol 2008; 10:902-11. PubMed
  • Mandinova A, Lefort K, Tommasi di Vignano A, Stonely W, Ostano P, Chiorino G, Iwaki H, Nakanishi J, Dotto GP. The FoxO3a gene is a key negative target of canonical Notch signalling in the keratinocyte UVB response. EMBO J 2008; 27:1243-54. PubMed
Hide